Alkermes Public Limited Company (ALKS)

Alkermes reported strong third-quarter 2025 financial results and announced the proposed acquisition of Avadel Pharmaceuticals in October 2025. Alkermes presented at the Jefferies Global Healthcare Conference in London in November 2025. The company completed its acquisition of Avadel Pharmaceuticals plc in February 2026, strengthening its position in sleep medicine. Alkermes reported its fourth-quarter and full-year 2025 financial results and provided financial expectations for 2026 in February 2026. Alkermes initiated the Phase 3 clinical program for alixorexton in narcolepsy in Q1 2026. Alkermes reported stronger-than-expected first-quarter 2026 financial results in May 2026, leading to a stock price increase. Analyst ratings in May 2026 included Needham & Company LLC raising its price target for ALKS to $50.00, while Piper Sandler reduced its target to $43.00 in March 2026. Truist Financial upgraded shares to a "strong-buy" in March 2026, and Wells Fargo & Company boosted its price target to $43.00 in February 2026. Royal Bank of Canada decreased its price target to $45.00 in February 2026. In May 2026, EVP Craig C. Hopkinson and EVP David Joseph Gaffin sold shares of the company's stock. Richard Pops, the long-serving CEO, announced plans to step down in August 2026, with Blair Jackson planned as his replacement.

Alkermes' products and services experience some demand seasonality. The company has noted "pronounced seasonality related to year-end ordering patterns in Q4" for some products. Additionally, "Q1 seasonality followed by growth in the second quarter and beyond" is an expectation for their proprietary products. This seasonality is also influenced by "typical Q1 patient copay and deductible reset dynamics, and historical demand patterns." For instance, in the first quarter of 2024, ARISTADA net sales reflected pronounced seasonality in prescriptions and a decrease in inventory in the channel. Similarly, LYBALVI's demand growth in Q1 2024 was partially offset by a decrease in inventory in the channel.

Alkermes Plc is a global biopharmaceutical company focused on developing innovative medicines for complex psychiatric and neurological disorders, operating within the healthcare sector, specifically in the biotechnology industry. The company's business centers on the research, development, and commercialization of pharmaceutical products, applying its neuroscience expertise to address unmet medical needs in areas such as addiction, serious mental illness, and sleep disorders. Its major proprietary products include LYBALVI for schizophrenia and bipolar I disorder, ARISTADA/ARISTADA INITIO for schizophrenia, VIVITROL for alcohol and opioid dependence, and LUMRYZ for narcolepsy. Alkermes also has partnered products that utilize its proprietary technologies, such as Vumerity for multiple sclerosis, Risperdal Consta for schizophrenia and bipolar I disorder, and Invega Sustenna/Xeplion for schizophrenia. The company is also advancing a pipeline of investigational candidates, including alixorexton for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.

Alkermes plc's global headquarters is located in Dublin, Ireland. The company maintains U.S. corporate offices and a research and development (R&D) facility in Massachusetts. Additionally, Alkermes has a GMP manufacturing facility in Ohio. Historically, the company also had a development and manufacturing business in Athlone, Ireland, which was sold on May 1, 2024.

Alkermes has maintained a positive brand reputation over the past year. It was named a "Best Large Workplace in BioPharma™" by Fortune Magazine in 2025 for the second consecutive year and certified as a "Great Place to Work" in the United States for 2024 and 2025. The company was recognized as a "Best Place for Working Parents" among Massachusetts businesses since 2022. Alkermes received the Platinum Bell Seal from Mental Health America since 2022 and was awarded a 2023 WorkWell Award from the Worksite Wellness Council of Massachusetts. It has also maintained a KeepWell Mark from the Irish Business and Employers Confederation (IBEC) since 2020.

Alkermes plc has a significant institutional ownership, with 369 institutional owners and shareholders holding a total of 178,766,257 shares as of May 1, 2026. Institutional ownership exceeded 94% of outstanding shares by early 2025. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Baker Bros. Advisors Lp, State Street Corp, Price T Rowe Associates Inc /md/, Renaissance Technologies Llc, American Century Companies Inc, Jpmorgan Chase & Co, Dimensional Fund Advisors Lp, Geode Capital Management, Llc, and Sarissa Capital.